Status:

COMPLETED

Brain GABA Levels and Treatment Response in Major Depressive Disorder

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

Mclean Hospital

Conditions:

Major Depressive Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE4

Brief Summary

This study will evaluate changes in brain gamma-aminobutyric acid (GABA) levels due to treatment with escitalopram in people with major depressive disorder.

Detailed Description

Major depressive disorder (MDD) is a severe form of depression. MDD can significantly interfere with an individual's thoughts, behavior, mood, and physical health. People who suffer from MDD often exp...

Eligibility Criteria

Inclusion

  • Meet diagnostic criteria for current Major Depressive Disorder
  • Men or women aged 18-65
  • Medication-free for one week prior to the start of the study
  • Agrees to use an effective form of contraception throughout the study

Exclusion

  • Anyone who is suicidal
  • Pregnant or breastfeeding women
  • Anyone with a serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease
  • Anyone with a history of seizure disorder or hypothyroidism
  • Anyone with a history of psychiatric disorders including bipolar disorder, schizophrenia, psychoses, or substance abuse (including alcohol abuse active within the last 12 months)
  • Anyone with a history of intolerance or multiple adverse drug reactions or allergy to (es)citalopram.
  • Patients who are currently taking medications active on GABA, including benzodiazepines.

Key Trial Info

Start Date :

September 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2009

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00464711

Start Date

September 1 2006

End Date

September 1 2009

Last Update

January 4 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Depression Clinical and Research Program, Massachusetts General Hospital

Boston, Massachusetts, United States, 02114